Back to search results
NCT04342429

Prospective Study of Intensity-Modulated Proton Therapy (IMPT) for Small Cell Lung Cancer

Recruiting
NAAges 18+InterventionalTreatment
Emory University
~30 participants
Updated 2025-07-15 on ClinicalTrials.gov
What's tested:Proton-beam Therapy for Small Cell Lung Cancer

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Patients with small cell lung cancer (SCLC) will be assessed with the intensity-modulated proton therapy (IMPT).
Measured over Up to 1 year from study start
+1 more outcome measured

Conditions

Small-cell Lung Cancer

Explore related trials

Lung Small Cell Carcinoma

Where it's being run

1 sites across 1 states
Georgia1

Study leadership

  • Kristin Higgins, MD · PRINCIPAL_INVESTIGATOR · Emory University-Winship Cancer Institute

Who to contact

Kristin Higgins, MD
[email protected]
404-778-0603
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Pathologically confirmed small cell lung cancer, limited or extensive stage.
Patients who are offered thoracic radiotherapy with intensity-modulated proton therapy (IMPT) techniques delivering 30-66 Gy in 15-33 fractions at 2 Gy per fraction, at the recommendation of the treating radiation oncologist.
Age 18 or greater

Exclusion

Prior radiation therapy which would provide significant dose overlap with the planned target volume(s)
Pregnancy

What this trial measures

  • Patients with small cell lung cancer (SCLC) will be assessed with the intensity-modulated proton therapy (IMPT).Up to 1 year from study start

    Patients enrolled will experience \<35% incidence of cardiac events at 1-year. Cardiac events included are acute heart disease, acute myocardial infarction, cardiomyopathy, dysrhythmia, heart failure, pericarditis, and pericardial effusion.

  • Determination of the optimal frequency of conebeam CT during treatment and subsequent need for adaptive re-planningUp to 1,2, and 5 years

    The optimal frequency of conebeam CT during treatment will be determined by a mixed model: * The local control, distant metastases, patterns of failure will be summarized as frequency and percentage. * Chi-square test will be used to test their relationships with other categorical variables. * General linear model will be used to measure their association with continuous covariates with and without adjusting for other factors